Developer docs
API playgroundTry for free, no card

Search company profiles

Cognivia

Full company profile

uuid0000ewh

Namestring
Cognivia
Legal namestring
Cognivia
Websiteurl
cognivia.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Cognivia is a Belgium-based AI company that develops behavioral intelligence solutions for pharmaceutical and biotechnology clinical trials. Founded in 2013 by Dominique Demolle (formerly operating as Tools4Patient), the company combines behavioral science, patient psychology data, and proprietary machine learning models to predict placebo response and patient dropout risk in randomized clinical trials. Its two commercial products are Placebell™, a covariate-adjustment solution that generates prognostic baseline covariates from psychological and behavioral inputs to reduce placebo-related data variability and improve statistical study power, and Cognivia™ Signal, a real-time behavioral-risk intelligence dashboard for monitoring dropout and placebo-response drivers during trial execution. Underlying inputs include the proprietary Multi-Dimensional Psychological Questionnaire (MPsQ) and Compl-AI engagement questionnaire, plus the Unik patient data management platform.

Cognivia's underlying AI stack relies on in-house machine learning models, including gaussian process with linear kernel, multivariate Cox models, and transfer learning approaches, trained on data from actual randomized placebo-controlled trials across pain, osteoarthritis, Parkinson's disease, Type 1 diabetes, and CNS indications. The Placebell methodology has received FDA acknowledgment as a "special case" of covariate adjustment aligned with existing FDA/EMA guidance. Cognivia sells through a direct enterprise field-sales motion to pharmaceutical sponsors, biotechnology companies, and CROs, complemented by scientific publications, webinars, and industry-conference presence (BIO, OARSI, CNS Summit, ATTD, USASP, Neupsig). Pricing is quote-based, structured as per-trial or enterprise software licensing with associated professional services. The company is venture-backed (€15.5M round in 2024 led by Vesalius Biocapital IV with SFPIM and Wallonie Entreprendre), operates from Mont-Saint-Guibert, Belgium, and has expanded into the United States through Cognivia USA Inc. in Red Bank, New Jersey. In 2025, Cognivia was recognized as one of the Top 50 Healthcare Technology Companies and was a Fierce Life Sciences Innovation Award finalist.

Short descriptiontext

Cognivia is a Belgium-based AI company that develops behavioral intelligence solutions, including Placebell and Cognivia Signal, to predict placebo response and patient dropout risk in pharmaceutical and biotechnology clinical trials. The company sells via direct enterprise licensing to trial sponsors and CROs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMont-saint-guibert, Belgium
HQ citystring
Mont-saint-guibert
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial analytics, placebo response prediction, patient dropout prediction, covariate adjustment software, behavioral intelligence platform
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Analytics Software
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Software/SaaS Platform Licensing
TypeSubscription Recurring
Description

Enterprise licensing of Placebell and Cognivia Signal platforms to pharmaceutical and biotech sponsors for use in clinical trials. Revenue generated through software subscriptions and usage fees.

cognivia.com
2Professional Services
TypeProfessional Services
Description

Consulting and implementation services to help clients integrate Cognivia's behavioral intelligence solutions into their clinical trial processes, including statistical analysis support and training.

cognivia.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Placebell™
Description

AI solution for predicting placebo response in clinical trials

prweb.com
+1 more record
Core offering1 text field

Cognivia develops AI-powered behavioral intelligence software for pharmaceutical and biotech clinical trials. Its core products, Placebell™ and Cognivia™ Signal, use machine learning models combined with proprietary psychological questionnaires (MPsQ, Compl-AI) to predict individual patient placebo response and dropout risk, reducing data variability by up to 30% and improving treatment effect estimation precision by 40%. The platform is licensed to clinical trial sponsors conducting Phase II and III studies across therapeutic areas including pain, osteoarthritis, Parkinson's disease, and Type 1 diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 30% reduction in clinical trial data variability
+4 more records
Product overview1 text field

Cognivia offers a unified platform of AI-powered behavioral intelligence solutions for clinical trials. The core portfolio consists of Placebell™ (predictive placebo response covariate adjustment) and Cognivia™ Signal (real-time dropout risk monitoring), both leveraging proprietary questionnaires (MPsQ, Compl-AI) and machine learning models. Placebell generates individual patient prognostic covariates for statistical analysis to reduce placebo-related variability and increase study power. Signal provides an early-warning dashboard for proactive patient retention management. These products are complementary—Signal monitors behavioral risks in real-time while Placebell provides covariate adjustment for retrospective analysis—enabling sponsors to address both proactive and analytical dimensions of behavioral variability in clinical trials.

Product and service5 records
1Placebell™
CategoryClinical Trial Covariate Adjustment Software
Description

A covariate adjustment solution that uses machine learning to predict individual patient placebo response based on psychological traits, expectations, and behavioral factors. Generates prognostic baseline covariates that reduce placebo-related data variability, increase statistical study power, and improve treatment effect estimation precision. Recognized as a finalist for the Fierce Life Sciences Innovation Award and acknowledged by FDA as aligned with covariate adjustment guidance.

2Cognivia™ Signal
CategoryClinical Trial Behavioral Risk Monitoring Software
Description

An early-warning behavioral risk intelligence dashboard for clinical trial teams that predicts participant dropout and monitors placebo response drivers in real time. Uses behavioral data and machine learning to help sponsors, CROs, and clinical teams detect and mitigate hidden behavioral risks before they disrupt trial performance. Achieves up to 93% sensitivity in predicting patient dropout with a C-index of 0.82.

3Compl-AI Questionnaire
CategoryPatient Assessment Tool
Description

A proprietary questionnaire used to collect baseline predictors of patient engagement including study site perception, belief in medicine, and health literacy. Data feeds predictive models for dropout and non-adherence risk assessment in clinical trials.

4MPsQ (Multi-Dimensional Psychological Questionnaire)
CategoryPatient Assessment Tool
Description

A proprietary questionnaire measuring patient personality traits, expectations, and psychosocial factors associated with placebo response. Collects data used as input for Placebell machine learning models to predict placebo response variability in clinical trials.

5Unik Patient Data Management Platform
CategoryClinical Trial Data Management Platform
Description

A data collection and management platform designed to capture and manage patient data while minimizing burden on patients and study teams. Supports patient engagement throughout clinical trials.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

Collaboration to advance behavioral intelligence integration across clinical research and clinical care settings. The partnership initially focuses on three key behavioral drivers: therapeutic non-adherence, missed appointments, and clinical trial retention. The goal is to make patient behavior measurable and actionable, enabling healthcare organizations to identify risk factors earlier and implement targeted interventions to improve patient adherence and trial execution.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on Phase II clinical trial for UBX101 intra-articular injection in osteoarthritis patients. Cognivia's Placebell model was used to predict placebo response and improve treatment effect estimation precision by 40%.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Medidata offers the Rave clinical trial platform including eCOA, randomization, and trial analytics. Direct comparable as a clinical trial SaaS provider serving pharma/biotech sponsors with software that improves trial execution and data quality.

TypeDirect peer
Description

Veeva provides life sciences cloud software including CTMS, eTMF, and clinical operations tools. Direct comparable as a SaaS platform serving pharma/biotech clinical development teams, overlapping with Cognivia's enterprise sales motion.

TypeDirect peer
Description

Cytel provides statistical software and services for clinical trial design, including East Bayes for adaptive trials. Direct comparable as a biostatistics/clinical analytics vendor targeting pharma/biostatistics decision-makers, similar to Placebell's buyer profile.

TypeDirect peer
Description

Clario delivers clinical trial endpoint technologies including eCOA, imaging, and respiratory solutions used in decentralized and hybrid trials. Direct comparable as a clinical trial technology vendor focused on endpoint quality and data capture.

TypeEmerging player
Description

Saama applies AI/ML to clinical trial data management, site monitoring, and patient journey analytics for pharma sponsors. Emerging peer with overlapping AI-for-clinical-trials value proposition but broader operational scope than Cognivia's behavioral focus.

6Deep 6 AI
TypeEmerging player
Description

Deep 6 AI uses AI to mine EHR data for clinical trial patient matching and recruitment. Emerging peer operating in the AI-for-clinical-trials space with overlapping buyer base (sponsors, CROs) but different functional focus.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and clinical analytics provider, offering technology alongside services including its E360 platform. Broad incumbent with overlapping clinical trial analytics capabilities but operating at much greater scale and scope.

8Oracle Health Sciences
TypeBroad incumbent
Description

Oracle Health Sciences provides Clinical One and other clinical trial applications for sponsors. Broad incumbent offering similar SaaS to pharma R&D with extensive enterprise IT integration but lacking Cognivia's behavioral AI specialization.

TypeEmerging player
Description

Science 37 operates a decentralized clinical trial platform addressing patient recruitment and retention. Emerging peer addressing overlapping trial execution pain points (especially dropout) with a different delivery model.

TypeEmerging player
Description

Medable provides a decentralized clinical trial platform focused on eCOA, eConsent, and remote patient engagement. Emerging peer addressing related trial execution and patient retention challenges faced by Cognivia's customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cognivia

Clinical Trial Analytics Softwarecognivia.com

Cognivia is a Belgium-based AI company that develops behavioral intelligence solutions, including Placebell and Cognivia Signal, to predict placebo response and patient dropout risk in pharmaceutical and biotechnology clinical trials. The company sells via direct enterprise licensing to trial sponsors and CROs.

What Cognivia does

Cognivia is a Belgium-based AI company that develops behavioral intelligence solutions for pharmaceutical and biotechnology clinical trials. Founded in 2013 by Dominique Demolle (formerly operating as Tools4Patient), the company combines behavioral science, patient psychology data, and proprietary machine learning models to predict placebo response and patient dropout risk in randomized clinical trials. Its two commercial products are Placebell™, a covariate-adjustment solution that generates prognostic baseline covariates from psychological and behavioral inputs to reduce placebo-related data variability and improve statistical study power, and Cognivia™ Signal, a real-time behavioral-risk intelligence dashboard for monitoring dropout and placebo-response drivers during trial execution. Underlying inputs include the proprietary Multi-Dimensional Psychological Questionnaire (MPsQ) and Compl-AI engagement questionnaire, plus the Unik patient data management platform.

Cognivia's underlying AI stack relies on in-house machine learning models, including gaussian process with linear kernel, multivariate Cox models, and transfer learning approaches, trained on data from actual randomized placebo-controlled trials across pain, osteoarthritis, Parkinson's disease, Type 1 diabetes, and CNS indications. The Placebell methodology has received FDA acknowledgment as a "special case" of covariate adjustment aligned with existing FDA/EMA guidance. Cognivia sells through a direct enterprise field-sales motion to pharmaceutical sponsors, biotechnology companies, and CROs, complemented by scientific publications, webinars, and industry-conference presence (BIO, OARSI, CNS Summit, ATTD, USASP, Neupsig). Pricing is quote-based, structured as per-trial or enterprise software licensing with associated professional services. The company is venture-backed (€15.5M round in 2024 led by Vesalius Biocapital IV with SFPIM and Wallonie Entreprendre), operates from Mont-Saint-Guibert, Belgium, and has expanded into the United States through Cognivia USA Inc. in Red Bank, New Jersey. In 2025, Cognivia was recognized as one of the Top 50 Healthcare Technology Companies and was a Fierce Life Sciences Innovation Award finalist.

Cognivia firmographics

Firmographics
Name
Cognivia
Legal name
Cognivia
Website
https://cognivia.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Cognivia is a Belgium-based AI company that develops behavioral intelligence solutions, including Placebell and Cognivia Signal, to predict placebo response and patient dropout risk in pharmaceutical and biotechnology clinical trials. The company sells via direct enterprise licensing to trial sponsors and CROs.
Ownership category
akta.pro rank

Cognivia industry classification

Industry
Product category
Clinical Trial Analytics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAK
Pharmacovigilance & Drug Safety Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Clinical trial analytics
  • Placebo response prediction
  • Patient dropout prediction
  • Covariate adjustment software
  • Behavioral intelligence platform

Where Cognivia is headquartered

Location

Headquarters

HQ city
Mont-saint-guibert
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Cognivia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Software/SaaS Platform Licensing: Enterprise licensing of Placebell and Cognivia Signal platforms to pharmaceutical and biotech sponsors for use in clinical trials. Revenue generated through software subscriptions and usage fees.
  2. Professional Services: Consulting and implementation services to help clients integrate Cognivia's behavioral intelligence solutions into their clinical trial processes, including statistical analysis support and training.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Cognivia product offering

Product offering

Core offering

Cognivia develops AI-powered behavioral intelligence software for pharmaceutical and biotech clinical trials. Its core products, Placebell™ and Cognivia™ Signal, use machine learning models combined with proprietary psychological questionnaires (MPsQ, Compl-AI) to predict individual patient placebo response and dropout risk, reducing data variability by up to 30% and improving treatment effect estimation precision by 40%. The platform is licensed to clinical trial sponsors conducting Phase II and III studies across therapeutic areas including pain, osteoarthritis, Parkinson's disease, and Type 1 diabetes.

Product overview

Cognivia offers a unified platform of AI-powered behavioral intelligence solutions for clinical trials. The core portfolio consists of Placebell™ (predictive placebo response covariate adjustment) and Cognivia™ Signal (real-time dropout risk monitoring), both leveraging proprietary questionnaires (MPsQ, Compl-AI) and machine learning models. Placebell generates individual patient prognostic covariates for statistical analysis to reduce placebo-related variability and increase study power. Signal provides an early-warning dashboard for proactive patient retention management. These products are complementary—Signal monitors behavioral risks in real-time while Placebell provides covariate adjustment for retrospective analysis—enabling sponsors to address both proactive and analytical dimensions of behavioral variability in clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Placebell™: AI solution for predicting placebo response in clinical trials
  • Cognivia™ Signal

Products and services

  • Placebell™ A covariate adjustment solution that uses machine learning to predict individual patient placebo response based on psychological traits, expectations, and behavioral factors. Generates prognostic baseline covariates that reduce placebo-related data variability, increase statistical study power, and improve treatment effect estimation precision. Recognized as a finalist for the Fierce Life Sciences Innovation Award and acknowledged by FDA as aligned with covariate adjustment guidance.
  • Cognivia™ Signal An early-warning behavioral risk intelligence dashboard for clinical trial teams that predicts participant dropout and monitors placebo response drivers in real time. Uses behavioral data and machine learning to help sponsors, CROs, and clinical teams detect and mitigate hidden behavioral risks before they disrupt trial performance. Achieves up to 93% sensitivity in predicting patient dropout with a C-index of 0.82.
  • Compl-AI Questionnaire A proprietary questionnaire used to collect baseline predictors of patient engagement including study site perception, belief in medicine, and health literacy. Data feeds predictive models for dropout and non-adherence risk assessment in clinical trials.
  • MPsQ (Multi-Dimensional Psychological Questionnaire) A proprietary questionnaire measuring patient personality traits, expectations, and psychosocial factors associated with placebo response. Collects data used as input for Placebell machine learning models to predict placebo response variability in clinical trials.
  • Unik Patient Data Management Platform A data collection and management platform designed to capture and manage patient data while minimizing burden on patients and study teams. Supports patient engagement throughout clinical trials.

Quantifiable outcome

  • 30% reduction in clinical trial data variability
  • +4 more outcomes

Companies that use Cognivia

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Cognivia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Cognivia partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Mayo CliniccoreStrategic or Co-development Partner · 23 June 2026Collaboration to advance behavioral intelligence integration across clinical research and clinical care settings. The partnership initially focuses on three key behavioral drivers: therapeutic non-adherence, missed appointments, and clinical trial retention. The goal is to make patient behavior measurable and actionable, enabling healthcare organizations to identify risk factors earlier and implement targeted interventions to improve patient adherence and trial execution.
  • Unity BiotechnologyminorStrategic or Co-development PartnerCollaboration on Phase II clinical trial for UBX101 intra-articular injection in osteoarthritis patients. Cognivia's Placebell model was used to predict placebo response and improve treatment effect estimation precision by 40%.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Cognivia competitors and assessment

Company assessment

Direct peers

  • Medidata Solutions (Dassault Systèmes): Medidata offers the Rave clinical trial platform including eCOA, randomization, and trial analytics. Direct comparable as a clinical trial SaaS provider serving pharma/biotech sponsors with software that improves trial execution and data quality.
  • Veeva Systems: Veeva provides life sciences cloud software including CTMS, eTMF, and clinical operations tools. Direct comparable as a SaaS platform serving pharma/biotech clinical development teams, overlapping with Cognivia's enterprise sales motion.
  • Cytel: Cytel provides statistical software and services for clinical trial design, including East Bayes for adaptive trials. Direct comparable as a biostatistics/clinical analytics vendor targeting pharma/biostatistics decision-makers, similar to Placebell's buyer profile.
  • Clario: Clario delivers clinical trial endpoint technologies including eCOA, imaging, and respiratory solutions used in decentralized and hybrid trials. Direct comparable as a clinical trial technology vendor focused on endpoint quality and data capture.

Emerging players

  • Saama Technologies: Saama applies AI/ML to clinical trial data management, site monitoring, and patient journey analytics for pharma sponsors. Emerging peer with overlapping AI-for-clinical-trials value proposition but broader operational scope than Cognivia's behavioral focus.
  • Deep 6 AI: Deep 6 AI uses AI to mine EHR data for clinical trial patient matching and recruitment. Emerging peer operating in the AI-for-clinical-trials space with overlapping buyer base (sponsors, CROs) but different functional focus.
  • Science 37: Science 37 operates a decentralized clinical trial platform addressing patient recruitment and retention. Emerging peer addressing overlapping trial execution pain points (especially dropout) with a different delivery model.
  • Medable: Medable provides a decentralized clinical trial platform focused on eCOA, eConsent, and remote patient engagement. Emerging peer addressing related trial execution and patient retention challenges faced by Cognivia's customers.

Broad incumbents

  • IQVIA: IQVIA is the world's largest CRO and clinical analytics provider, offering technology alongside services including its E360 platform. Broad incumbent with overlapping clinical trial analytics capabilities but operating at much greater scale and scope.
  • Oracle Health Sciences: Oracle Health Sciences provides Clinical One and other clinical trial applications for sponsors. Broad incumbent offering similar SaaS to pharma R&D with extensive enterprise IT integration but lacking Cognivia's behavioral AI specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Cognivia social profiles

Digital presence

Cognivia compliance and trust

Trust signal

Compliance3 records

Cognivia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cognivia leadership team

Management profile

Number of profiles

Profiles11 records

Cognivia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cognivia funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cognivia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cognivia

What does Cognivia do?

Cognivia develops AI-powered behavioral intelligence software for pharmaceutical and biotech clinical trials. Its core products, Placebell™ and Cognivia™ Signal, use machine learning models combined with proprietary psychological questionnaires (MPsQ, Compl-AI) to predict individual patient placebo response and dropout risk, reducing data variability by up to 30% and improving treatment effect estimation precision by 40%. The platform is licensed to clinical trial sponsors conducting Phase II and III studies across therapeutic areas including pain, osteoarthritis, Parkinson's disease, and Type 1 diabetes.

Is Cognivia a public or private company?

Cognivia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cognivia founded?

Cognivia was founded in 2013. It employs 11 to 50 people.

Where is Cognivia based?

Cognivia is headquartered in Mont-saint-guibert, Belgium, in the Europe region.

How does Cognivia make money?

Two revenue lines are on record. Software/SaaS Platform Licensing is the primary driver. The others are professional Services.

Who are Cognivia's main competitors?

Direct peers on record are Medidata Solutions (Dassault Systèmes), Veeva Systems, Cytel and Clario. Emerging players are Saama Technologies, Deep 6 AI, Science 37 and Medable. Broad incumbents are IQVIA and Oracle Health Sciences.

Does Cognivia have an API?

No public API is recorded for Cognivia.

What industry is Cognivia in?

Cognivia's product category is Clinical Trial Analytics Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAK, Pharmacovigilance & Drug Safety Software. Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Technology NetworksAI in Clinical Trials: Disentangling the “Noise” of Patient BehaviorTechnology Networks published an interview with Dr. Dominique Demolle, co-founder and CEO of Cognivia, discussing how AI can quantify and model patient behavioral factors—such as motivation, adherence, and expectations—that contribute to variability in clinical trial outcomes. Dr. Demolle outlined three main opportunities for AI: improving trial design through predictive models, supporting proactive risk management during trial execution, and disentangling signal from noise during data interpretation. The article notes that regulators, including the FDA, are developing frameworks for credible AI adoption in clinical development, though barriers around data silos, change management, and model transparency remain.PR NewswireCognivia Announces Collaboration to Advance Behavioral Intelligence Across Clinical Research and Clinical CareCognivia announced a collaboration with Mayo Clinic to advance behavioral intelligence across clinical research and clinical care settings. The partnership will initially focus on three key drivers of outcomes: non-adherence, missed appointments, and clinical trial retention, leveraging Cognivia's behavioral intelligence capabilities and Mayo Clinic's expertise in patient care. The collaboration aims to make patient behavior measurable and actionable, enabling healthcare organizations to identify behavioral risks earlier and implement targeted interventions to improve patient adherence and trial execution.PR NewswireCognivia Announces Collaboration to Advance Behavioral Intelligence Across Clinical Research and Clinical CareCognivia announced a collaboration with Mayo Clinic to advance behavioral intelligence across clinical research and clinical care, initially focusing on non-adherence, missed appointments, and clinical trial retention. The partnership aims to make patient behavior measurable and actionable, enabling healthcare organizations to identify behavioral risks earlier and support stronger trial retention and more predictable study execution. Mayo Clinic has a financial interest in the referenced technology and will use any revenue to support its not-for-profit mission in patient care, education, and research.PR NewswireCognivia annonce une collaboration avec la Mayo Clinic pour faire progresser l'intégration de l'intelligence comportementale en recherche clinique et en pratique médicaleCognivia announced a collaboration with Mayo Clinic to advance the integration of behavioral intelligence in clinical research and medical practice. The partnership will initially focus on three key determinants: therapeutic non-adherence, missed appointments, and clinical trial retention — behavioral factors that contribute to rising costs, operational inefficiencies, and outcome variability. The collaboration aims to make patient behaviors measurable and actionable, enabling healthcare organizations to identify risk factors earlier and tailor interventions more effectively.PR NewswireLearn How to Reduce Patient Dropout in Clinical Trials in Less than One HourCognivia, an AI company specializing in behavioral variability solutions for clinical research, announced an upcoming live webinar scheduled for February 24, 2026, to demonstrate its new product Cognivia Signal. The product uses AI-driven behavioral intelligence to help sponsors and clinical research organizations proactively identify patient and site-level dropout risk in clinical trials, shifting from reactive to predictive patient retention strategies. Patient dropout is cited as one of the leading drivers of costly delays and data loss in clinical trials, making predictive behavioral intelligence a strategic focus for the company's commercial offerings.YahooNew AI solution offers real-time peek into the mind of clinical trial participantsCognivia launched Cognivia Signal, a real-time behavioral risk dashboard for clinical trial sponsors. In a Type 1 Diabetes trial, it predicted 93% of dropouts before they occurred. The company says it aims to reduce trial delays and placebo-related noise.PR NewswireNew AI solution offers real-time peek into the mind of clinical trial participantsCognivia launched Cognivia Signal, a real-time behavioral risk dashboard for clinical trial sponsors. In a Type 1 Diabetes trial, it predicted 93% of dropouts before they occurred. The company says it aims to reduce trial delays and placebo-related noise.PR NewswireNew Study Boosts Trial Precision in Measuring Pain, Mood, and FatigueCognivia published a peer-reviewed study in the Journal of Pain presenting a covariate adjustment method that significantly improves how subjective endpoints like pain, mood, and fatigue are analyzed in clinical trials. In a real-world Phase III acute lumbar pain case study, applying composite psychological predictors from Cognivia's Placebell platform increased trial precision by up to 23.4%. The approach automates the creation of prognostic covariates, making it scalable and applicable beyond pain trials to any study with high-variability endpoints.ClinicaltrialvanguardBehavioral Science: The Untapped Asset in Obesity Trial StrategyCognivia promotes its behavioral modeling platforms, Placebell and Compl-AI, as essential tools for improving the integrity and efficiency of obesity clinical trials by accounting for patient psychological traits. The article argues that integrating these tools helps sponsors reduce trial noise, predict non-adherence, and distinguish pharmacologic effects from placebo responses, thereby accelerating time-to-market in a competitive landscape led by Novo Nordisk and Eli Lilly.PR NewswireStrategiczne finansowanie firmy Cognivia w wysokości 15,5 mln euro na rozwój leków, które obejmuje zastosowanie rozwiązań AI-MLCognivia secured 15.5 million euros in strategic funding from investors Vesalius Biocapital IV, SFPIM, and WE to advance its AI-ML technologies for optimizing pharmaceutical clinical trials. The capital will be used to deploy predictive solutions like Placebell™ and Compl-AI, which aim to reduce placebo effects and improve patient adherence, thereby accelerating drug development. Additionally, Cognivia plans to expand its operations by establishing a subsidiary in the United States to strengthen its commercial and R&D presence.